DE59010933D1
(de)
|
1989-09-12 |
2003-05-08 |
Hoffmann La Roche |
TFN-bindende Proteine
|
ATE309376T1
(de)
*
|
1990-06-28 |
2005-11-15 |
Hoechst Ag |
Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
|
JPH06502301A
(ja)
*
|
1990-08-29 |
1994-03-17 |
サントル オスピタリエ レジオナル デ ナント |
安定タンパク質コアに結合されたタンパク質ポリリガンド
|
US5621083A
(en)
*
|
1991-11-04 |
1997-04-15 |
Xoma Corporation |
Immunotoxins comprising ribosome-inactivating proteins
|
US6146850A
(en)
*
|
1991-11-04 |
2000-11-14 |
Xoma Corporation |
Proteins encoding gelonin sequences
|
US5837491A
(en)
*
|
1991-11-04 |
1998-11-17 |
Xoma Corporation |
Polynucleotides encoding gelonin sequences
|
GB9316989D0
(en)
*
|
1993-08-16 |
1993-09-29 |
Lynxvale Ltd |
Binding molecules
|
DK0659439T3
(da)
*
|
1993-12-24 |
2002-01-14 |
Merck Patent Gmbh |
Immunkonjugater
|
WO1995021258A1
(en)
|
1994-02-01 |
1995-08-10 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Fusion proteins that include antibody and nonantibody portions
|
IT1271688B
(it)
*
|
1994-08-04 |
1997-06-04 |
Menarini Ricerche Sud Spa |
Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
|
US5541087A
(en)
*
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
DE69523857T2
(de)
*
|
1994-09-16 |
2002-06-13 |
Merck Patent Gmbh |
Immunokonjugate
|
US6949244B1
(en)
|
1995-12-20 |
2005-09-27 |
The Board Of Trustees Of The University Of Kentucky |
Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
DE19716892C1
(de)
*
|
1997-04-22 |
1998-09-03 |
Gsf Forschungszentrum Umwelt |
Expression von Immunglobulin-Zytokin-Fusionsproteinen in malignen B-Zellen
|
EP1489100B1
(en)
*
|
1997-12-08 |
2016-06-15 |
Merck Patent GmbH |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
EP1093457B8
(en)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
HUP0101352A3
(en)
*
|
1998-04-15 |
2003-08-28 |
Lexigen Pharmaceuticals Corp L |
Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
|
RU2217168C2
(ru)
*
|
1998-04-17 |
2003-11-27 |
Лексиген Фармасьютикэлс Корпорейшн |
Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора простагландина
|
MXPA01008110A
(es)
*
|
1999-02-12 |
2002-10-23 |
Scripps Research Inst |
Metodos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias anti-angiogenicas e inmunoterapia.
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
JP4793971B2
(ja)
*
|
1999-08-09 |
2011-10-12 |
メルク パテント ゲーエムベーハー |
複合サイトカイン−抗体複合体
|
EP1731531B1
(en)
*
|
1999-08-09 |
2012-05-30 |
Merck Patent GmbH |
Multiple cytokine-antibody complexes
|
GB9926084D0
(en)
*
|
1999-11-03 |
2000-01-12 |
King S College London |
Recombinant fusion molecules
|
GB2360771A
(en)
*
|
2000-03-28 |
2001-10-03 |
Antisoma Res Ltd |
Compounds for targeting
|
DE10019157A1
(de)
*
|
2000-04-18 |
2001-11-15 |
Stefan Duebel |
Verfahren zum Einbringen von Liganden in lebende Zellen
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
ES2609016T3
(es)
|
2000-06-16 |
2017-04-18 |
Human Genome Sciences, Inc. |
Anticuerpos que se unen inmunoespecíficamente a BLyS
|
US6911204B2
(en)
|
2000-08-11 |
2005-06-28 |
Favrille, Inc. |
Method and composition for altering a B cell mediated pathology
|
DE10045591A1
(de)
*
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
AU1994402A
(en)
|
2000-11-28 |
2002-06-11 |
Mediummune Inc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
EP1366058B1
(en)
|
2001-02-09 |
2011-01-26 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
US7208582B2
(en)
|
2001-04-13 |
2007-04-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
EP1256354A1
(en)
*
|
2001-05-11 |
2002-11-13 |
Schering Corporation |
Methods for treating cancer
|
ES2437992T3
(es)
|
2001-05-25 |
2014-01-15 |
Human Genome Sciences, Inc. |
Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
EP1499352A4
(en)
|
2002-04-12 |
2006-10-11 |
Medimmune Inc |
ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
|
GB0209896D0
(en)
*
|
2002-04-30 |
2002-06-05 |
Molmed Spa |
Conjugate
|
EP1531848A4
(en)
|
2002-06-10 |
2007-03-28 |
Vaccinex Inc |
DIFFERENTIAL EXPRESSED GENE IN BREAST AND BLADDER CANCER AND CODED POLYPEPTIDE
|
DK2248899T3
(en)
|
2003-03-19 |
2015-06-29 |
Biogen Ma Inc |
Nogo receptor-binding protein
|
EP2266628A3
(en)
|
2003-05-13 |
2012-01-18 |
Novartis Vaccines and Diagnostics, Inc. |
Method of determining the susceptibility to bone meatastases by EPhA2 expression
|
SI1703893T1
(sl)
|
2003-12-23 |
2012-07-31 |
Genentech Inc |
Nova protitelesa proti il in uporaba le teh
|
ATE443724T1
(de)
|
2004-01-22 |
2009-10-15 |
Merck Patent Gmbh |
Antikrebs-antikörper mit reduzierter komplementfixierung
|
EP1776136B1
(en)
|
2004-06-24 |
2012-10-03 |
Biogen Idec MA Inc. |
Treatment of conditions involving demyelination
|
WO2006017673A2
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
WO2006078776A2
(en)
|
2005-01-19 |
2006-07-27 |
The Trustees Of The University Of Pennsylvania |
Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
|
WO2007002543A2
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
SG163591A1
(en)
|
2005-07-08 |
2010-08-30 |
Biogen Idec Inc |
Sp35 antibodies and uses thereof
|
EP1904652A2
(en)
|
2005-07-08 |
2008-04-02 |
Brystol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
EP2500030B2
(en)
|
2005-11-04 |
2018-08-08 |
Genentech, Inc. |
Use of complement pathway inhibitors to treat ocular diseases
|
AU2006311828B2
(en)
|
2005-11-04 |
2013-07-11 |
Biogen Ma Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
EP1945261A4
(en)
|
2005-11-07 |
2010-05-12 |
Scripps Research Inst |
COMPOSITIONS AND METHODS FOR CONTROLLING THE SPECIFICITY OF TISSUE FACTOR SIGNALING
|
JP5312039B2
(ja)
|
2005-12-02 |
2013-10-09 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
脱髄の関与する状態の処置
|
KR101397290B1
(ko)
|
2005-12-30 |
2014-05-21 |
메르크 파텐트 게엠베하 |
감소한 면역원성을 가지는 항-cd19 항체
|
AU2006332138B2
(en)
|
2005-12-30 |
2012-03-22 |
Merck Patent Gmbh |
Interleukin-12p40 variants with improved stability
|
PT1981902E
(pt)
|
2006-01-27 |
2015-11-02 |
Biogen Ma Inc |
Antagonistas dos recetores nogo
|
TW200813231A
(en)
|
2006-04-13 |
2008-03-16 |
Novartis Vaccines & Diagnostic |
Methods of treating, diagnosing or detecting cancer
|
SG172684A1
(en)
|
2006-06-07 |
2011-07-28 |
Bioalliance Cv |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
CA2656700A1
(en)
*
|
2006-07-06 |
2008-01-10 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
RS53120B
(en)
|
2006-08-28 |
2014-06-30 |
Kyowa Hakko Kirin Co. Ltd. |
ANTAGONISTIC HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE HUMAN LIGHT
|
US9382327B2
(en)
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
NZ577274A
(en)
|
2006-12-18 |
2012-10-26 |
Genentech Inc |
Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
|
PL2099826T3
(pl)
|
2007-01-05 |
2014-04-30 |
Univ Zuerich |
Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
PT2068887E
(pt)
|
2007-01-09 |
2014-06-23 |
Biogen Idec Inc |
Anticorpos sp35 e suas utilizações
|
MX2009008178A
(es)
|
2007-02-02 |
2009-10-26 |
Biogen Idec Inc |
Uso de semaforina 6a para promover la mielinizacion y la diferenciacion de oligodendrocitos.
|
WO2008112988A2
(en)
|
2007-03-14 |
2008-09-18 |
Novartis Ag |
Apcdd1 inhibitors for treating, diagnosing or detecting cancer
|
TW200902547A
(en)
|
2007-04-27 |
2009-01-16 |
Genentech Inc |
Potent, stable and non-immunosuppressive anti-CD4 antibodies
|
US8969024B2
(en)
|
2007-08-28 |
2015-03-03 |
Abbvie Biotechnology Ltd |
Compositions and methods comprising binding proteins for adalimumab
|
BRPI0815983A2
(pt)
|
2007-08-29 |
2018-05-22 |
Sanofi Aventis |
anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
US8236316B2
(en)
|
2007-11-21 |
2012-08-07 |
Oregon Health & Science University |
Anti-factor XI monoclonal antibodies and methods of use thereof
|
RU2528738C2
(ru)
|
2007-12-18 |
2014-09-20 |
Биоэллаенс К.В. |
Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения
|
WO2009082485A1
(en)
|
2007-12-26 |
2009-07-02 |
Vaccinex, Inc. |
Anti-c35 antibody combination therapies and methods
|
EP2260102A1
(en)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
MX2010011206A
(es)
|
2008-04-16 |
2010-11-12 |
Biogen Idec Inc |
Metodo para aislar biomacromoleculas usando glicol de polialquileno y metales de transicion.
|
EP2315779A2
(en)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Compositions comprising antibodies to lingo or fragments thereof
|
ES2549877T3
(es)
|
2008-09-07 |
2015-11-02 |
Glyconex Inc. |
Anticuerpo antiglucoesfingolípido de tipo I extendido, derivados del mismo y utilización
|
BRPI0923157B1
(pt)
|
2008-12-19 |
2021-12-28 |
University Of Zürich |
Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática
|
US20120003235A1
(en)
|
2008-12-31 |
2012-01-05 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
CN102428103B
(zh)
|
2009-03-24 |
2015-04-08 |
泰华生物制药美国公司 |
抗light的人源化抗体及其使用
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
WO2010121766A1
(en)
|
2009-04-22 |
2010-10-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
JP6059013B2
(ja)
|
2009-05-08 |
2017-01-11 |
バクシネックス インコーポレーティッド |
抗cd100抗体およびこれを使用するための方法
|
MX2012001882A
(es)
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
AU2010315101B2
(en)
|
2009-11-04 |
2016-01-28 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
EP2542578A1
(en)
|
2010-03-05 |
2013-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Smoc1, tenascin-c and brain cancers
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
CN103124788B
(zh)
*
|
2010-05-21 |
2016-01-13 |
梅里麦克制药股份有限公司 |
双特异性融合蛋白
|
WO2011154485A1
(en)
|
2010-06-10 |
2011-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
SG186985A1
(en)
|
2010-07-09 |
2013-02-28 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
EP2609431B1
(en)
|
2010-08-27 |
2017-05-10 |
University of Zurich |
Method for target and drug validation in inflammatory and/or cardiovascular diseases
|
JP6097690B2
(ja)
|
2010-09-02 |
2017-03-15 |
ヴァクシネックス, インコーポレイテッド |
抗cxcl13抗体およびそれを用いる方法
|
EP2614080A1
(en)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
MX345092B
(es)
|
2010-10-11 |
2017-01-17 |
Univ Zuerich |
Anticuerpos anti-tau humanos,.
|
EP2640738A1
(en)
|
2010-11-15 |
2013-09-25 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
WO2012080518A1
(en)
|
2010-12-17 |
2012-06-21 |
Neurimmune Holding Ag |
Human anti-sod1 antibodies
|
AR085911A1
(es)
|
2011-03-16 |
2013-11-06 |
Sanofi Sa |
Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
|
WO2012170072A1
(en)
|
2011-06-06 |
2012-12-13 |
Immungene, Inc. |
Engineered antibody-tnfsf member ligand fusion molecules
|
EP2717911A1
(en)
|
2011-06-06 |
2014-04-16 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
LT2723379T
(lt)
|
2011-06-23 |
2018-10-25 |
Biogen International Neuroscience Gmbh |
Anti-alfa sinukleiną rišančios molekulės
|
WO2013034579A1
(en)
|
2011-09-05 |
2013-03-14 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Biosynthetic gene cluster for the production of peptide/protein analogues
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
US9221907B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Anti-GPR49 monoclonal antibodies
|
CA2853951A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
EP2773373B1
(en)
|
2011-11-01 |
2018-08-22 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
US9416179B2
(en)
|
2011-12-05 |
2016-08-16 |
X-Body, Inc. |
PDGF receptor beta binding polypeptides
|
EP2800583A1
(en)
|
2012-01-02 |
2014-11-12 |
Novartis AG |
Cdcp1 and breast cancer
|
AU2013225812B2
(en)
|
2012-03-02 |
2017-11-30 |
Vaccinex, Inc. |
Methods for the treatment of B cell-mediated inflammatory diseases
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
CA2868353C
(en)
|
2012-03-28 |
2023-10-31 |
Sanofi |
Antibodies to bradykinin b1 receptor ligands
|
WO2013144240A1
(en)
|
2012-03-29 |
2013-10-03 |
Friedrich Miescher Institute For Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
EP2847216A1
(en)
|
2012-05-07 |
2015-03-18 |
Sanofi |
Methods for preventing biofilm formation
|
JP2015518829A
(ja)
|
2012-05-14 |
2015-07-06 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
運動ニューロンに関する状態の処置のためのlingo−2アンタゴニスト
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
JP5868549B2
(ja)
|
2012-05-24 |
2016-02-24 |
マウントゲイト グループ リミテッド |
狂犬病感染の予防および治療に関する組成物および方法
|
EP2866831A1
(en)
|
2012-06-29 |
2015-05-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
EP2870242A1
(en)
|
2012-07-05 |
2015-05-13 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
MY181648A
(en)
|
2012-08-24 |
2020-12-30 |
Univ California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
CA2896066C
(en)
|
2012-12-21 |
2022-07-12 |
Biogen Ma Inc. |
Human anti-tau antibodies
|
JP6407165B2
(ja)
|
2012-12-31 |
2018-10-17 |
ニューリミューン ホールディング エイジー |
ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体
|
AU2013205589A1
(en)
|
2013-03-08 |
2014-09-25 |
Vaccinex, Inc. |
Anti-CXCL13 antibodies and associated epitope sequences
|
US9872899B2
(en)
|
2013-03-15 |
2018-01-23 |
Biological Mimetics, Inc. |
Immunogenic human rhinovirus (HRV) compositions
|
NZ712300A
(en)
|
2013-03-15 |
2020-07-31 |
Sutter West Bay Hospitals |
Falz for use as a target for therapies to treat cancer
|
SG11201509982UA
(ja)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
WO2015019286A1
(en)
|
2013-08-07 |
2015-02-12 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment friedreich's ataxia
|
ES2770507T3
(es)
|
2013-08-13 |
2020-07-01 |
Sanofi Sa |
Anticuerpos dirigidos contra el inhibidor de los activadores del plasminógeno de tipo 1 (PAI-1) y usos de los mismos
|
TWI592426B
(zh)
|
2013-08-13 |
2017-07-21 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
PT3060229T
(pt)
|
2013-10-24 |
2021-10-07 |
Astrazeneca Ab |
Formulações aquosas estáveis de anticorpos
|
US10272117B2
(en)
|
2014-02-24 |
2019-04-30 |
Celgene Corporation |
Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
CA2943242A1
(en)
|
2014-03-21 |
2015-09-24 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
EP3126397B1
(en)
|
2014-04-04 |
2020-01-29 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
EP3154579A1
(en)
|
2014-06-13 |
2017-04-19 |
Friedrich Miescher Institute for Biomedical Research |
New treatment against influenza virus
|
US10308935B2
(en)
|
2014-06-23 |
2019-06-04 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
|
US20170165261A1
(en)
|
2014-07-01 |
2017-06-15 |
Brian Arthur Hemmings |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
JP2017522886A
(ja)
|
2014-07-29 |
2017-08-17 |
ニューリミューン ホールディング エイジー |
ヒト由来抗ハンチンチン(htt)抗体及びその使用
|
EP3197557A1
(en)
|
2014-09-24 |
2017-08-02 |
Friedrich Miescher Institute for Biomedical Research |
Lats and breast cancer
|
CN108064248B
(zh)
|
2014-09-30 |
2022-03-15 |
生物控股有限公司 |
人源抗二肽重复(dpr)抗体
|
JP6672293B2
(ja)
|
2014-10-31 |
2020-03-25 |
メディミューン,エルエルシー |
改善された製造方法
|
NZ733055A
(en)
|
2014-12-11 |
2023-03-31 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
WO2016112270A1
(en)
|
2015-01-08 |
2016-07-14 |
Biogen Ma Inc. |
Lingo-1 antagonists and uses for treatment of demyelinating disorders
|
PT3265123T
(pt)
|
2015-03-03 |
2023-02-01 |
Kymab Ltd |
Anticorpos, usos e métodos
|
BR112017020955A2
(pt)
|
2015-03-31 |
2018-07-10 |
Medimmune Limited |
forma de il33, formas mutadas de il33, anticorpos, ensaios e métodos de uso dos mesmos
|
WO2017048902A1
(en)
|
2015-09-15 |
2017-03-23 |
Board Of Regents, The University Of Texas System |
T-cell receptor (tcr)-binding antibodies and uses thereof
|
CN108367048B
(zh)
|
2015-10-02 |
2022-08-12 |
银溪制药股份有限公司 |
用于组织修复的双特异性治疗性蛋白质
|
EP3368566A1
(en)
|
2015-10-28 |
2018-09-05 |
Friedrich Miescher Institute for Biomedical Research |
Tenascin-w and biliary tract cancers
|
CA3010601A1
(en)
|
2016-01-08 |
2017-07-13 |
Bioalliance C.V. |
Tetravalent anti-psgl-1 antibodies and uses thereof
|
JP2019509322A
(ja)
|
2016-03-22 |
2019-04-04 |
バイオノミクス リミテッド |
抗lgr5モノクローナル抗体の投与
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
KR102680924B1
(ko)
|
2017-05-05 |
2024-07-02 |
백시넥스 인코포레이티드 |
인간 항-세마포린 4d 항체
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
MX2020005473A
(es)
|
2017-11-27 |
2020-08-27 |
Purdue Pharma Lp |
Anticuerpos humanizados que se dirigen al factor tisular humano.
|
EP3728302A1
(en)
|
2017-12-19 |
2020-10-28 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
EP3924386A4
(en)
|
2019-02-13 |
2023-01-04 |
The Brigham & Women's Hospital, Inc. |
ANTI-PERIPHERAL LYMPH NODE RESPONSIBLE ANTIBODIES AND USES THEREOF
|
CN113939534A
(zh)
|
2019-04-03 |
2022-01-14 |
建新公司 |
具有降低的断裂的抗αβTCR结合多肽
|
CA3141492A1
(en)
|
2019-05-24 |
2020-12-03 |
Sanofi |
Methods for treating systemic sclerosis
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022153194A1
(en)
|
2021-01-13 |
2022-07-21 |
Memorial Sloan Kettering Cancer Center |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
US20240115721A1
(en)
|
2021-01-13 |
2024-04-11 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
IL305301A
(en)
|
2021-02-19 |
2023-10-01 |
Us Health |
Single domain antibodies neutralizing SARS CoV-2
|